HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials by Volk JE, Hessol NA, Gray GE, Kublin JG, Churchyard G, Mlisana K, Nchabeleng M, Buchbinder SP, Bekker L